O uso do alendronato de sódio na osteoporose

Mychael Pereira Cordeiro; Filipe Abdalla dos Reis; Gabriel Bogalho Nogueira; Carlos Alberto Giglio; Paulo de Tarso Camillo de Carvalho; Ana Carulina Guimarães Belchior

doi:10.5585/conssaude.v8i2.1510

Authors

Mychael Pereira Cordeiro UNAERP
Filipe Abdalla dos Reis FISIO&SPORT; UNIDERP; UFMS
Gabriel Bogalho Nogueira UNAES/ANHANGUERA; FISIO&SPORT
Carlos Alberto Giglio UNAERP
Paulo de Tarso Camillo de Carvalho UFMS
Ana Carulina Guimarães Belchior UNIDERP

DOI:

https://doi.org/10.5585/conssaude.v8i2.1510

Keywords:

Alendronato de sódio, Bisfosfonatos, Osteoporose.

Abstract

Osteoporosis is a gradual and systemic disease characterized by reduction of the bone mass and deterioration of the microarchitecture, resulting in bone fragility. The sodium alendronate is a drug of a biphosphonate class, being a powerful inhibitor specific of the bone reabsorption mediated by osteoclasts. The study aimed to verify the effects of the sodium alendronate in patients with osteoporosis. To reach this purpose, it was executed a literature review using a related bibliography and scientific articles of Medline, Bireme, Pubmed, Lilacs, Scielo and Cochrane databases. Through this study, it was verified that the sodium alendronate is considered a therapeutic agent for prevention and treatment of osteoporosis in men and women.

Downloads

Author Biographies

Mychael Pereira Cordeiro, UNAERP

1 Fisioterapeuta Especialista em Fisioterapia Músculo Esquelética – Universidade de Ribeirão Preto (UNAERP) 2 Fisioterapeuta da Equipe FISIO&SPORT – Campo Grande - MS

Filipe Abdalla dos Reis, FISIO&SPORT; UNIDERP; UFMS

2 Fisioterapeuta da Equipe FISIO&SPORT – Campo Grande - MS 3 Professor Mestre do Curso de Fisioterapia – Universidade para o Desenvolvimento do Estado e da Região do Pantanal (UNIDERP), Campo Grande – MS. 4 Programa de Pós Graduaçào em Saúde e Desenvolvimento da região Centro-Oeste – UFMS, Campo Grande - MS